@article{Yaghoubian_Niktale_Yazdi_Ghorani_Rashed_Hashemian_2021, title={Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19}, volume={31}, url={https://www.pagepressjournals.org/bam/article/view/9518}, DOI={10.4081/ejtm.2021.9518}, abstractNote={<p>The antiviral effectiveness of allicin (L-cysteine) has been shown by numerous studies in both levels of clinical and animals. The aim of this study was to evaluate the therapeutic effect of allicin (L-cysteine) on clinical presentation and prognosis. In the current study, 66 patients with COVID-19 based on clinical, radiological presentations and RT-PCR results, were enrolled in two groups of placebo and allicin. In the both allicin (L-cysteine) and placebo groups (n=33 in each group), the capsules were prescribed two times a day for two weeks. Clinical signs and symptoms, blood parameters and chest CT scan were evaluated before and two weeks after treatment. The results showed that allicin (L-cysteine) could significantly impact on improvement of signs and symptoms of COVID-19 after two weeks of treatment in comparison to placebo. Allicin (L-cysteine) not only improve the clinical signs, but also ameliorate the lab and radiological data, which suggest a therapeutic effect for this agent in COVID-19. Our data suggest the therapeutic effect of allicin (L-cysteine) on COVID-19 through improvement of clinical symptoms and acceleration of the healing process.</p>}, number={2}, journal={European Journal of Translational Myology}, author={Yaghoubian, Hosein and Niktale, Hossein and Yazdi, Arash Peivandi and Ghorani, Vahideh and Rashed, Masoud Mahdavi and Hashemian, Amir Masoud}, year={2021}, month={Jun.} }